Loading clinical trials...
Loading clinical trials...
A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF-06651600 IN ADULT AND ADOLESCENT ALOPECIA AREATA (AA) SUBJECTS WITH 50% OR GREATER SCALP HAIR LOSS
Conditions
Interventions
PF-06651600 Induction Dose
PF-06651600 Maintenance Dose #1
+3 more
Locations
155
United States
The University of Alabama at Birmingham Hospital Outreach Lab
Birmingham, Alabama, United States
The University of Alabama at Birmingham, Department of Dermatology
Birmingham, Alabama, United States
The University of Alabama at Birmingham, Department of Dermatology
Birmingham, Alabama, United States
Mosaic Dermatology
Beverly Hills, California, United States
University of California, Irvine, Department of Dermatology, Dermatology Clinical Research Center
Irvine, California, United States
Dermatology Specialists, Inc.
Murrieta, California, United States
Start Date
December 3, 2018
Primary Completion Date
December 31, 2020
Completion Date
June 24, 2021
Last Updated
February 24, 2022
NCT06826196
NCT06562270
NCT07133308
NCT06327581
NCT07023302
NCT07152119
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions